Pregledni rad
Elevated Blood Pressure and Arterial Hypertension – New Guidelines from a Pharmacotherapeutic Perspective
Andrej Belančić
Puni tekst: hrvatski pdf 363 Kb
str. 7-13
preuzimanja: 55
citiraj
APA 6th Edition
Belančić, A. (2025). Elevated Blood Pressure and Arterial Hypertension – New Guidelines from a Pharmacotherapeutic Perspective. Medicus, 34. (1. KRM zdravlje), 7-13. Preuzeto s https://hrcak.srce.hr/index.php/338511
MLA 8th Edition
Belančić, Andrej. "Elevated Blood Pressure and Arterial Hypertension – New Guidelines from a Pharmacotherapeutic Perspective." Medicus, vol. 34., br. 1. KRM zdravlje, 2025, str. 7-13. https://hrcak.srce.hr/index.php/338511. Citirano 05.12.2025.
Chicago 17th Edition
Belančić, Andrej. "Elevated Blood Pressure and Arterial Hypertension – New Guidelines from a Pharmacotherapeutic Perspective." Medicus 34., br. 1. KRM zdravlje (2025): 7-13. https://hrcak.srce.hr/index.php/338511
Harvard
Belančić, A. (2025). 'Elevated Blood Pressure and Arterial Hypertension – New Guidelines from a Pharmacotherapeutic Perspective', Medicus, 34.(1. KRM zdravlje), str. 7-13. Preuzeto s: https://hrcak.srce.hr/index.php/338511 (Datum pristupa: 05.12.2025.)
Vancouver
Belančić A. Elevated Blood Pressure and Arterial Hypertension – New Guidelines from a Pharmacotherapeutic Perspective. Medicus [Internet]. 2025 [pristupljeno 05.12.2025.];34.(1. KRM zdravlje):7-13. Dostupno na: https://hrcak.srce.hr/index.php/338511
IEEE
A. Belančić, "Elevated Blood Pressure and Arterial Hypertension – New Guidelines from a Pharmacotherapeutic Perspective", Medicus, vol.34., br. 1. KRM zdravlje, str. 7-13, 2025. [Online]. Dostupno na: https://hrcak.srce.hr/index.php/338511. [Citirano: 05.12.2025.]
Puni tekst: engleski pdf 363 Kb
str. 7-13
preuzimanja: 24
citiraj
APA 6th Edition
Belančić, A. (2025). Elevated Blood Pressure and Arterial Hypertension – New Guidelines from a Pharmacotherapeutic Perspective. Medicus, 34. (1. KRM zdravlje), 7-13. Preuzeto s https://hrcak.srce.hr/index.php/338511
MLA 8th Edition
Belančić, Andrej. "Elevated Blood Pressure and Arterial Hypertension – New Guidelines from a Pharmacotherapeutic Perspective." Medicus, vol. 34., br. 1. KRM zdravlje, 2025, str. 7-13. https://hrcak.srce.hr/index.php/338511. Citirano 05.12.2025.
Chicago 17th Edition
Belančić, Andrej. "Elevated Blood Pressure and Arterial Hypertension – New Guidelines from a Pharmacotherapeutic Perspective." Medicus 34., br. 1. KRM zdravlje (2025): 7-13. https://hrcak.srce.hr/index.php/338511
Harvard
Belančić, A. (2025). 'Elevated Blood Pressure and Arterial Hypertension – New Guidelines from a Pharmacotherapeutic Perspective', Medicus, 34.(1. KRM zdravlje), str. 7-13. Preuzeto s: https://hrcak.srce.hr/index.php/338511 (Datum pristupa: 05.12.2025.)
Vancouver
Belančić A. Elevated Blood Pressure and Arterial Hypertension – New Guidelines from a Pharmacotherapeutic Perspective. Medicus [Internet]. 2025 [pristupljeno 05.12.2025.];34.(1. KRM zdravlje):7-13. Dostupno na: https://hrcak.srce.hr/index.php/338511
IEEE
A. Belančić, "Elevated Blood Pressure and Arterial Hypertension – New Guidelines from a Pharmacotherapeutic Perspective", Medicus, vol.34., br. 1. KRM zdravlje, str. 7-13, 2025. [Online]. Dostupno na: https://hrcak.srce.hr/index.php/338511. [Citirano: 05.12.2025.]
Sažetak
Despite the availability of effective therapies, arterial hypertension remains a leading global health challenge. Recently published guidelines from the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC) aim to simplify and optimize hypertension treatment. These updated guidelines emphasize fixed-dose dual therapy as first-line treatment, standardize target blood pressure values to 120–129 mmHg for most patients, and highlight the role of out-of-office monitoring and non-pharmacological strategies. ESC guidelines introduce new blood pressure classifications, promote early intervention in high-risk populations, and recommend systematic screening for primary aldosteronism. Additionally, they support deprescribing in frail patients and call for objective adherence assessment. Notably, agents not traditionally classified as antihypertensives—such as GLP-1 receptor agonists and SGLT-2 inhibitors—demonstrate promising blood pressure-lowering effects and cardio-renal-metabolic benefits. This review offers a pharmacotherapeutic perspective on key updates, including initiation criteria, fourth-line treatment choices, positioning of beta-blockers, and the therapeutic potential of novel agents, advocating for a pragmatic, patient-centered approach in contemporary hypertension management.
Ključne riječi
arterial hypertension, guidelines, pharmacotherapy, fixed therapies, non-pharmacological measures
Hrčak ID:
338511
URI
https://hrcak.srce.hr/338511
Datum izdavanja:
27.10.2025.
Podaci na drugim jezicima:
hrvatski
Posjeta: 133
*
